兔抗IDH3G多克隆抗體

Background:

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. NAD(+)-dependent isocitrate dehydrogenases catalyze the allosterically regulated rate-limiting step of the tricarboxylic acid cycle. Each isozyme is a heterotetramer that is composed of two alpha subunits, one beta subunit, and one gamma subunit.

Applications:

ELISA, WB, IHC

Name of antibody:

IDH3G

Immunogen:

Fusion protein of human IDH3G

Full name:

isocitrate dehydrogenase 3 (NAD+) gamma

Synonyms：

H-IDHG

SwissProt:

P51553

ELISA Recommended dilution:

1000-2000

IHC positive control:

Human thyroid cancer and human cervical cancer

IHC Recommend dilution:

25-100

WB Predicted band size:

43 kDa

WB Positive control:

A431 cells and mouse brain tissue

WB Recommended dilution:

200-1000